- About Us
- Services & Solutions
- Investor Relations
- News & Resources
Offering End-to-End Solutions
Shanghai, January 15th, 2024 – WuXi XDC（2268.HK）, a leading Contract Research, Development, and Manufacturing Organization (CRDMO) focused on ADC and other types of bioconjugates market, congratulates OnCusp Therapeutics on the completion of $100 million Series A financing round. OnCusp Therapeutics is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. The proceeds from this financing will be used to advance CUSP06, an ADC targeting CDH6, toward clinical proof-of-concept.
As OnCusp’s strategic service partner, WuXi XDC provides one-stop service for CUSP06 with world leading ADC platform capabilities both with high quality and at a fast speed, accelerating the development timeline and enabling the successful IND approval. Having obtained FDA IND clearance in 3Q 2023, CUSP06 will be in a first-in-human Phase I study in the US. The successful collaboration between WuXi XDC and OnCusp Therapeutics on the CUSP06 project exemplifies a win-win partnership model by leveraging the core strengths of both companies to accelerate the translation from early research to innovative therapeutics.
Dr. Bing Yuan, CEO of OnCusp Therapeutics, stated, “WuXi XDC is an exceptional business partner with a leading ADC development platform and in-depth capabilities. By combining WuXi XDC’s strength in CMC development with our expertise in oncology, we look forward to accelerating the development of CUSP06 for the benefit of cancer patients around the world.”
Dr. Jimmy Li, CEO of WuXi XDC, commented, “Congratulations to OnCusp Therapeutics on reaching this significant milestone. We are honored to provide our one-stop technical platform and high-quality services, enabling OnCusp Therapeutics to accelerate the asset from the preclinical to clinical stage. We wish the company continued success in bringing breakthrough therapies to patients. As a leader in bioconjugation, WuXi XDC is committed to supporting clients worldwide and contributing to the innovation and development of bioconjugate drugs.”
About OnCusp Therapeutics
OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building startup biotechs, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients.
About WuXi XDC
WuXi XDC Cayman Inc. (“WuXi XDC” or the “Company”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com.